Accessible screening tests and inclusive management strategies may limit the global cervical cancer incidence rate.
Federal lawmakers have renewed efforts to pass legislation ensuring Medicare coverage of multi-cancer early detection (MCED) tests.
Although PRS technology and adoption still have a way to go, it is progressing quickly, especially in the cancer and oncology space.
Prostate Cancer: National Guidelines Have Not Stopped Overuse of Low-Value PSA Screening in Older Males
New research suggests that the call to rein in low-value prostate cancer screening seems to be falling on deaf ears.
The acquisition of the Johns Hopkins spin out and its liquid biopsy ctDNA test will significantly strengthen Quest’s oncology offerings.